Skip to main content
Actinium Pharmaceuticals, Inc. logo

Actinium Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · ATNM ISIN · US00507W2061 LEI · 549300LCY1NZSXCQDT45 US Manufacturing
Open in API
Filings indexed 493 across all filing types
Latest filing 2017-01-03 Director's Dealing
Country US United States of America
Listing US ATNM

About Actinium Pharmaceuticals, Inc.

https://www.actiniumpharma.com/

Actinium Pharmaceuticals, Inc. is a clinical-stage company focused on developing targeted radiotherapies for patients with cancers lacking effective treatment options. The company's platform utilizes potent radioisotopes, such as the alpha-emitter Actinium-225, conjugated to monoclonal antibodies to precisely deliver radiation to cancer cells. Its clinical pipeline addresses hematologic malignancies and solid tumors. Key programs include Iomab-B, a targeted conditioning agent for bone marrow transplant in patients with relapsed or refractory Acute Myeloid Leukemia (AML), and Actimab-A, a CD33-targeting therapy for AML. The company is also advancing ATNM-400, a novel non-PSMA therapeutic for prostate cancer, and developing its proprietary Actinium-225 manufacturing technology and infrastructure.

Recent filings

Filing Released Lang Actions
OWNERSHIP DOCUMENT
Director's Dealing
2017-01-03 English
CURRENT REPORT
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, dated December 21, 2016, reporting on the results of the 2016 Annual Meeting of Stockholders. It details the voting outcomes on various proposals including election of a director, ratification of the independent auditor, stock plan amendment, and executive compensation vote. The content is focused on the official results of shareholder votes at the Annual General Meeting. The document length is 3735 characters, which is relatively short but contains detailed voting results, not just an announcement of a report. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2016-12-22 English
CURRENT REPORT
Regulatory Filings Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, as indicated by the header and references to the Securities Exchange Act of 1934. It reports the entry into a material definitive agreement, specifically an amendment to the company's stock plan. The document does not contain financial statements or detailed financial performance data, nor is it an earnings release or annual/interim report. It is a regulatory filing reporting a corporate event (amendment to stock plan) rather than a full report or presentation. The length is 3297 characters, which is relatively short and consistent with a current report filing. Therefore, the appropriate classification is Regulatory Filings (RNS).
2016-12-14 English
DEFINITIVE ADDITIONAL MATERIALS
Remuneration Information Classification · 95% confidence The document is titled 'DEFA14A' and is described as 'Definitive Additional Materials' related to a Schedule 14A Proxy Statement. It provides updated information about the nomination of directors, which is supplementary to a previously filed Proxy Statement. The content focuses on board nominations and director qualifications, which are typical topics in proxy materials. The document length is 3316 characters, which is relatively short and consistent with an additional or supplemental filing rather than a full report. Given these factors, the document is best classified as 'Remuneration Information' (DEF 14A), which covers proxy statements and related materials concerning executive and director compensation and nominations.
2016-12-14 English
OWNERSHIP DOCUMENT
Director's Dealing
2016-12-12 English
DEFINITIVE ADDITIONAL MATERIALS
Remuneration Information Classification · 95% confidence The document is titled 'DEFA14A' which corresponds to 'Definitive Additional Materials' related to a Proxy Statement (Schedule 14A). It provides supplemental information regarding the Summary Compensation Table from a previously filed Proxy Statement. The content focuses on executive compensation details and is an addendum to a proxy filing, not a standalone remuneration report or a full proxy statement. Given the nature of the document as additional materials to a proxy statement, the most appropriate classification is 'DEF 14A' which covers remuneration information and related proxy materials.
2016-12-08 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.